N/A N=20 iWalk Hands Free Crutch
Healthy
Primary: Whole Body Angular Momentum-sagittal Plane — 0.051; 0.079; 0.095; 0.155 dimensionless
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=100 Pilocarpine Microneedles for Sweat Induction (PMN-SI)
Cystic Fibrosis
Primary: Amount of Sweat Collected — 41.2; 43.8 mg
N/A N=197 Utilizing Augmented Reality as an Adjunct for Smoking Cessation
Smoking
Primary: Urge to Smoke - Pilot Testing — 4.58; 1.42 score on a scale
N/A N=26 Cervical Ripening With Cook Catheter Plus Low Dose Oxytocin
Cervical Ripening
Primary: Time to Delivery (in Hours) — 27; 23 hours — p=0.208
Phase 2 N=12 Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)
High Tumor Mutation Burden · High TMB (Tumor Mutation Burden) · MSS (Microsatellite Stable)
Primary: Objective Response Rate (ORR) in Patients With MSI (Microsatellite Unstable)-Negative Solid Tumor Malignancies With a Mutator Phenotype — 5 Participants
N/A N=52 Text 2 Connect- Texting Intervention for Mental Health Treatment Utilization
Depression · Suicidal Ideation
Primary: Engagement With Intervention: Text Message Check-ins — 5 # of text messages sent to participants
Phase 3 N=44 The Effects of Inhaled Nitric Oxide After Fontan Operation
Congenital Heart Defect
Primary: Length of Hospital Stay Following Fontan — 11.2; 11 days
N/A N=120 Study of Opioid Use After Lumbar and Cervical Spine Surgery
Low Back Pain · Opiate Addiction · Neck Pain
Primary: Number of Opioid Medication Prescriptions — 5.0; 5.1 prescriptions count
Phase 2 N=151 Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
Diffuse Astrocytoma · Anaplastic Astrocytoma · Astrocytoma
Primary: LGG Cohort: Overall Response Rate (ORR) by Central Independent Assessment Using Response Assessment in Neuro-Oncology (RANO) Criteria — 46.6; 10.8 Percentage of…
Phase 3 N=300 A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis
Primary Axillary Hyperhidrosis
Primary: The Number of Participants With Treatment Emergent Adverse Events Cumulative to Week 48 by Maximum Severity — 27; 55; 29; 58 Participants
N/A N=16 An Exploratory PET-study of Deposition, Disposition and Brain Uptake of [11C]Nicotine After Inhalation of 2 Nicotine Formulations Via the myBluTM E-cigarette in Smokers
Healthy Volunteers
Primary: Lung PET — 35.5; 31.0 Percentage of nicotine
Phase 4 N=43 SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine
Covid19 · SARS-CoV2 Infection
Primary: Neutralizing Antibody (NAb) Level — 2242.47; 2695.21; 2196.74; 888.80 titer
N/A N=31 Nasal Bridles and Repeat Endoscopic Procedures for Endoscopic Nasoenteric Tubes
Feeding Disorders
Primary: Repeat Endoscopy to Replace Dislodged Feeding Tube — 3; 2 Participants
Phase 3 N=430 A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries
HIV Infections
Primary: Change From Baseline in Acceptability of Implementation Measure (AIM-Imp) Score in SSP at Month 12 — 3.8; 3.9; 0.28; 0.33 Scores on a scale
Phase 1 N=14 Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
Squamous Cell Carcinoma of the Head and Neck · Carcinoma of the Head and Neck
Primary: Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling — 0; 4; 0; 0 Lymph Nodes